Blue Moon Metals begins trading on NASDAQ under BMM symbol

Blue Moon Metals Inc. (TSXV: MOON) announced its common shares will commence trading on the Nasdaq Capital Market under the symbol "BMM" on January 26. The company's shares will continue trading on the TSX Venture Exchange under "MOON" and the Frankfurt Stock Exchange under "8SX0," but will cease trading on OTCQX under "BMOOF."

The company appointed Peter Madsen to its Board of Directors, with his term beginning concurrent with the Nasdaq listing. Madsen brings over four decades of financial markets experience, having worked at firms including L.F. Rothschild, Bear Stearns, and Alpha Investment Management. He currently serves as Senior Managing Director at U.S. brokerage firm Deer Isle Capital.

"Our Nasdaq listing represents a significant step forward for Blue Moon Metals," said Christian Kargl-Simard, CEO. "It strengthens our presence in the U.S. market and provides additional opportunities to engage with a wider investor base."

The mining company operates three brownfield polymetallic projects: the Nussir copper-gold-silver project in Norway, the NSG copper-zinc-gold-silver project in Norway, and the Blue Moon zinc-gold-silver-copper project in the United States. The company expects to complete its acquisition of the Springer processing plant in Nevada, which will process ores from the Blue Moon Mine in Mariposa County, California.

Major shareholders include Oaktree Capital Management and Hartree Partners LP, which form the company's largest shareholder group. Blue Moon stated it expects significant U.S. shareholder growth and liquidity improvement during 2026.

The company plans to acquire additional high-grade critical metals underground mines in the Western United States that can be developed with ore transported to the Springer facility for processing.

You May Also Be Interested In

• IQM names Barbara Venneman to board ahead of planned Nasdaq listing
• Shell pauses $3 billion share buyback program due to ARC deal
• Diana Shipping urges Genco shareholders to vote against poison pill